Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2020—ArcherDX announced a nonexclusive, multiyear partnership with Illumina intended to broaden access of next-generation-sequencing–based oncology testing, including companion diagnostics for therapeutic selection, personalized monitoring, and recurrence surveillance IVD tests, upon FDA approval.
February 2020—Eppendorf has launched 25-mL conical tubes. It is the same diameter as a conventional 50-mL conical tube and comes with either the SnapTec snap cap or screw cap, both of which have high centrifugation stability. The SnapTec cap allows for single-handed opening and closing of the cap. The wide opening of the tube, combined with the lower height, is designed to offer easy sample access.
February 2020—DriBank Labs announced the availability of its DriBank system for preserving, storing, and shipping laboratory samples. The system preserves small (≤ 3 g or 50 µL) laboratory biological samples at room temperature (20˚C) for up to six months using desiccants contained inside a replaceable and rechargeable cartridge, eliminating the need for chemical fixatives or refrigerants. It accepts samples in a variety of media including microscope slides, microcentrifuge tubes, cell culture dishes, swabs, and others.
February 2020—Genomenon announced a partnership with Sophia Genetics that includes incorporating Genomenon’s Mastermind genomic search engine into the Sophia platform and the Alamut suite.
February 2020—NeuMoDx Molecular and Sentinel Diagnostics announced a partnership to develop diagnostic assays for the NeuMoDx 96 and 288 molecular systems. Sentinel’s real-time PCR assays will be adapted to the NeuMoDx 96 and 288 molecular systems and will incorporate Sentinel’s STAT-NAT technology, which provides the ability to stabilize the activity of a PCR mix, allowing room-temperature storage and transport. The test menu pipeline for the systems will include assays to detect and monitor post-transplant infections, parasitic and hospital-acquired infections, and respiratory infections, and for pharmacogenetics applications.
February 2020—Baebies announced that its Finder platform is CE marked as an in vitro diagnostic device and commercially available in Europe and other countries that recognize the CE mark. The platform includes an instrument and a cartridge, which tests for glucose-6-phosphate dehydrogenase from 50 μL of whole blood. Features of the platform include an eight-inch-wide footprint, preloaded consumables with all necessary reagents, and a turnaround time of approximately 15 minutes from sample introduction.
February 2020—Qiagen introduced QIAseq Multimodal Panels, which offer a consolidated workflow to enrich DNA variants, RNA fusions, and gene expression levels from a single sample, with input as low as 10 ng of total nucleic acid. It reduces the workflow to approximately nine hours, the company reports, by eliminating the need for two workflows from separate DNA and RNA samples.
February 2020—Myriad Genetics announced that the FDA has approved BRACAnalysis CDx for use as a companion diagnostic to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with PARP inhibitor olaparib (Lynparza, AstraZeneca). BRACAnalysis CDx is the first FDA-approved genetic test for this indication, the company reports. Myriad Genetics, 801-584-3600
February 2020—The FDA authorized marketing of the Cobas VivoDx MRSA (Roche Molecular Systems) diagnostic test based on bacterial viability and novel technology to detect methicillin-resistant Staphylococcus aureus bacterial colonization. The Cobas VivoDx MRSA test uses a new bacteriophage technology based on bioluminescence to detect MRSA from nasal swab samples in as few as five hours compared with 24 to 48 hours for conventional culture. The FDA reviewed data from performance studies in which the Cobas VivoDx MRSA test correctly identified
February 2020—Karius announced that JAMA Oncology published a clinical study showing that the Karius test detected bloodstream infections before the onset of clinical symptoms in high-risk pediatric patients with relapsed or refractory leukemia (Goggin KP, et al. Epub ahead of print Dec. 19, 2019. doi:10.1001/jamaoncol.2019.4120). The study was performed by researchers at St. Jude Children’s Research Hospital.
